Objective. Rheumatoid arthritis (RA) is characterized by the presence of anti-citrullinated protein antibodies (ACPAs); nevertheless, the origin, specificity, and functional properties of ACPAs remain poorly understood. The aim of this study was to characterize the evolution of ACPAs by sequencing the plasmablast antibody repertoire at serial time points in patients with established RA.
Objective. Rheumatoid arthritis (RA) is characterized by the presence of anti-citrullinated protein antibodies (ACPAs); nevertheless, the origin, specificity, and functional properties of ACPAs remain poorly understood. The aim of this study was to characterize the evolution of ACPAs by sequencing the plasmablast antibody repertoire at serial time points in patients with established RA.
Methods. Blood samples were obtained at up to 4 serial time points from 8 individuals with established RA who were positive for ACPAs by the anti-cyclic citrullinated peptide test. CD19+CD3ÀIgDÀCD14ÀCD20À CD27+CD38++ plasmablasts were isolated by single-cell sorting and costained with citrullinated peptide tetramers to identify ACPA-expressing plasmablasts. Cell-specific oligonucleotide barcodes were utilized, followed by large-scale sequencing and bioinformatics analysis, to obtain error-corrected, paired heavy-and light-chain antibody gene sequences for each B cell.
Results. Bioinformatics analysis revealed 170 persistent plasmablast lineages in the RA blood, of which 19% included multiple isotypes. Among IgGand IgA-expressing plasmablasts, significantly more IgA-expressing than IgG-expressing persistent lineages were observed (P < 0.01). Shared complementarity-determining region 3 sequence motifs were identified across subjects. A subset of the plasmablast lineages included members derived from later time points with divergent somatic hypermutations that encoded antibodies that bind an expanded set of citrullinated antigens. Furthermore, these recombinant, differentially mutated plasmablast antibodies formed immune complexes that stimulated higher macrophage production of tumor necrosis factor (TNF) compared to antibodies representing earlier time point-derived lineage members that were less mutated.
Conclusion. These findings demonstrate that established RA is characterized by a persistent IgA ACPA response that exhibits ongoing affinity maturation. This observation suggests the presence of a persistent mucosal antigen that continually promotes the production of IgA plasmablasts and their affinity maturation and epitope spreading, thus leading to the generation of ACPAs that bind additional citrullinated antigens and more potently stimulate macrophage production of TNF.
Rheumatoid arthritis (RA) is characterized by the generation of autoantibodies, including rheumatoid factor and anti-citrullinated protein antibodies (ACPAs) (1) . In the present study, we sequenced the plasmablast antibody repertoire over serial time points in patients with established RA to gain insights into the evolution of ACPAs, and to further define the role of ACPAs in promoting the pathogenesis of RA.
ACPAs target citrullinated epitopes arising from posttranslational modifications of arginine to citrulline by peptidylarginine deiminase (PAD) (2) . Epitope spreading of ACPAs precedes the onset of clinical symptoms in RA (3) . Previous studies have demonstrated that recombinant murine ACPAs can increase the severity of arthritis in mice (4, 5) . A therapeutic strategy of B cell depletion using rituximab provides clinical benefit in patients with seropositive RA (6) , and its efficacy is associated with mild reductions in circulating ACPA levels (7) . A mucosal drive has been postulated in the pathogenesis of RA (8) . Cigarette smoking represents a risk factor for ACPA+ RA (9) , and ACPAs are detectable in the sputum and/or serum from subjects with early RA and individuals at risk for developing RA (10) .
ACPAs may contribute to the pathogenesis of RA by stimulating immune effector cells, including macrophages (11) , which produce tumor necrosis factor (TNF) and other cytokines (12) . Macrophages can be activated by proinflammatory cytokines, immune complexes (ICs), and Toll-like receptor (TLR) agonists (13) . Studies from our laboratory and others have shown that ICs composed of RA blood-derived ACPAs and citrullinated proteins stimulate macrophages, both from the blood (14) and from the synovial fluid (15) , to produce TNF. These ACPA ICs stimulate macrophages via Fcc receptor type II (FccRII) (15) (16) (17) (18) and TLR-4 (16, 17) . Nevertheless, the role of ACPAs and the mechanisms by which affinity maturation and the evolving ACPA repertoire contribute to the development and persistence of RA remain unclear.
In this study, we utilized our cell-barcoding antibody repertoire sequencing method (19) to investigate the evolution of the ACPA B cell response in RA. Previous studies utilizing this approach have focused on the blood IgG repertoire at a single time point in patients with established RA (19) or the IgA and IgG repertoire at a single time point in subjects prior to RA development or in those with early RA (20) . In this study, at up to 4 serial time points, we sequenced plasmablasts, which have been shown to produce ACPAs (19, 21) , from the blood of 8 individuals with established RA who were positive for ACPAs by the anti-cyclic citrullinated peptide test (anti-CCP+). Our findings from bioinformatics analysis revealed plasmablast lineages in the RA blood that persisted across serial time points and revealed shared heavy-chain (HC) and lightchain (LC) third complementarity-determining region (CDR3) motifs across subjects. Using antigen microarrays and enzyme-linked immunosorbent assays (ELISAs), we demonstrated that, compared to plasmablast lineage members derived from earlier time points, a subset of lineage members from later time points that were differentially mutated encoded antibodies targeting additional citrullinated antigens. In vitro macrophage stimulation assays revealed that these later time point-derived, affinitymatured, differentially mutated recombinant plasmablast antibodies generated ICs that more potently stimulated macrophage production of TNF, a mechanism that may be postulated to promote the pathogenesis of RA.
PATIENTS AND METHODS
Human blood samples. After obtaining written informed consent from all potential study subjects under protocols approved by the Stanford University Institutional Review Board, blood samples were collected in heparin tubes at serial time points, at intervals of ≥2 months apart, from 8 anti-CCP+ patients with RA (Table 1 ). All subjects were recruited from the VA Palo Alto Healthcare System (Palo Alto, California). Patients with RA met the American College of Rheumatology 1987 and 2010 classification criteria (22, 23) . Monocyte-derived macrophages were generated from blood samples that were obtained from the Stanford Blood Center. Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient centrifugation with Ficoll-Paque PLUS (GE Healthcare Life Sciences).
Single-cell sorting of plasmablasts. CD19+CD3ÀIgDÀ CD14ÀCD20ÀCD27+CD38++ plasmablasts were single-cell sorted using a BD FACSAria (BD Biosciences) as described previously (19, 24) (for more details see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40587/abstract). For staining of PBMCs, we used fluorophore-conjugated antibodies against CD19 (HIB19; BioLegend), CD3 (UCHT1; BD Biosciences), IgD (IA6-2; BD Biosciences), CD14 (MφP9; BD Bioinformatics analysis of immunoglobulin sequences. Sequence data were processed, and the sequences of the HC V-D-J regions and LC V-J regions were aligned using ImMunoGeneTics (IMGT) HighV-Quest (25) . Thereafter, phylogenetic trees were generated using a previously described method (19, 20, 24) (for more details, see Supplementary Methods at http://onlinelibrary.wiley.com/doi/10.1002/art.40587/abstract). IMGT-based analysis of V-region somatic hypermutations (SHMs) was utilized to compare mutation levels across subjects and across time points. Clonal families and persistent lineages were assigned on the basis of shared, IMGT-based assignments of HC and LC V-J-region genes and meeting the threshold of 60% identity (according to the Levenshtein distance [26] ) within the HC and LC CDR3 regions, similar to that previously determined for other lineages with different identity thresholds (27) .
To evaluate HC and LC CDR3 sequence motifs across patients, cluster analysis was performed using CD-HIT (28, 29) . Persistent lineage-derived HC and LC CDR3 sequences were linked by a 4-X spacer and clustered according to a cutoff level of 70% identity; results were visualized with igraph in R (30) . For clusters containing >1 subject, linked HC and LC CDR3 sequences were used to generate sequence logos (WebLogo [31] ). Plasmablast sequences were aligned to germline V-Jregion genes using Clustal X version 2.0 (32), input to IgTree (33) , and lineage trees were visualized in Graphviz version 2.38 (34) . Insertions and D-region gene segments were included in this mutation count from germline. Visualization of the alignments with Geneious version 7.0.3 (35) identified amino acid differences between lineage members.
Generation of recombinant monoclonal antibodies. A subset of subject-derived plasmablast antibody sequences representing clonal families/lineages and/or antibodies binding to the citrullinated peptide tetramers, as well as negative control antibodies, were recombinantly produced in Dr. Robinson's laboratory at Stanford University or by staff at LakePharma (San Carlos, CA). To ensure consistency in the characterization assays, all antibodies were expressed on the human IgG1 Fc domain. In-house production was done as described previously, using an Expi293 Expression System (ThermoFisher) with Expi293F cells (36) (see Supplementary Methods, http://onlinelibrary.wiley.com/ doi/10.1002/art.40587/abstract).
Characterization of antibody binding specificities. The QUANTA Lite CCP3.1 IgG/IgA kit (Inova) was used to test the CCP-binding activity of plasma and recombinant antibodies, in accordance with the manufacturer's protocol. For recombinant antibodies, an activity cutoff level of 3 SD above the mean value for negative control antibodies was used. Recombinant antibodies were further screened for binding to citrullinated and native peptides/proteins by planar and bead-based antigen arrays, as previously described (3, 37) . Planar arrays (50 lg/ml) and beadbased arrays (25 lg/ml) were used to evaluate antibody binding to~350 proteins/peptides or 40 proteins/peptides, respectively. Using fluorophore-conjugated anti-human IgG secondary antibodies to detect binding, the median fluorescence intensities were determined from quadruplicate print spots (planar array) or >50 beads (bead array).
ELISAs were performed using peptides and fulllength proteins citrullinated in vitro with PAD from rabbit skeletal muscle (Sigma) or recombinant PAD-4 (see Supplementary Methods, http://onlinelibrary.wiley.com/doi/10.1002/ art.40587/abstract). ELISA plates were coated with full-length proteins (1-5 lg/ml) and peptides (10-15 lg/ml) diluted in bicarbonate/carbonate buffer (pH 9.5) (as described in Supplementary Methods, http://onlinelibrary.wiley.com/doi/10.1002/ art.40587/abstract), and horseradish peroxidase-based detection was carried out with a 1-Step Ultra TMB-ELISA substrate (ThermoFisher). The fold change in activity, based on an activity cutoff level of 3 SD above the mean activity of negative controls, was calculated.
Macrophage stimulation assays. Macrophages were isolated and cultured from plated PBMCs by adhesion with 30 ng/ml of human macrophage colony-stimulating factor (M-CSF; PeproTech) as described previously (16, 17) (for more details, see Supplementary Methods at http://onlinelibrary. wiley.com/doi/10.1002/art.40587/abstract). This approach is commonly used for culturing macrophages and has been proposed as a reference standard (13) . To form plate-bound ICs, the plates were coated with 50 ll of protein (20 lg/ml), washed with phosphate buffered saline (PBS), and blocked with 1% low-endotoxin bovine serum albumin in PBS (150 ll). Thereafter, 50 ll of recombinant, subject-derived antibodies (50 lg/ ml) was added. After further washing, differentiated macrophages were added (50,000 cells/well) in medium (5% fetal bovine serum, without human M-CSF). To block FccRII and/ or TLR-4, cells were preincubated (at 37°C) for 1 hour with anti-CD32 (clone IV.3; StemCell Technologies) and/or an InSolution TLR-4 inhibitor, TAK-242 (EMD Millipore). Lipopolysaccharide (50 ng/ml; Sigma-Aldrich) was used as a positive control. After 24 hours of incubation (at 37°C), supernatants were harvested and levels of TNF were measured by ELISA (PeproTech).
Statistical analysis. Statistical analysis was performed in GraphPad Prism (version 7). One-way or two-way analyses of variance followed by Tukey's test for multiple comparisons were used. P values less than 0.05 were considered significant. The relationship between the number of tender and swollen joints and the mean normalized size of each clonal family was determined by Spearman's rank correlation.
RESULTS
Profiling the evolution of the blood plasmablast antibody repertoire across serial time points in RA. We used our cell barcode-enabled antibody repertoire sequencing method (19) to sequence the blood CD19+ CD3ÀIgDÀCD14ÀCD20ÀCD27+CD38++ plasmablast antibody repertoires from up to 4 serial time points in samples from 8 anti-CCP+ patients with established RA (see Table 1 for patient characteristics). Bioinformatics analyses assigned sequencing reads and obtained errorcorrected consensus sequences of the HC V-D-J regions and LC V-J regions of each plasmablast. These data sets were used to construct phylogenetic trees that provided an overview of the plasmablast antibody repertoire, including identification of clonally expanded families/ lineages and antibodies that were only observed once (singletons) ( Figure 1A ).
The representative phylogenetic tree shown in Figure 1A depicts trends observed in multiple RA subjects, and these observations are further highlighted in the inset images. We identified clonal lineages with representatives in multiple time points (insets 1 and 2 in Figure 1A ), hereafter referred to as persistent lineages. Some clonal expansions consisted of plasmablasts expressing antibodies of a single isotype (insets 2 and 3 in Figure 1A ), whereas others included multiple isotypes (insets 1 and 4 in Figure 1A) .
By combining bioinformatics analysis of the sequence data with flow-based data from staining with the citrullinated peptide tetramers, we identified candidate ACPA-expressing clonal expansions and singletons ( Figure 1A) . The combination of different affinities and cell-surface receptor expression among clonal family members may lead to differential binding and could lead to false-negative findings among the sorted plasmablasts. Conversely, the increased avidity of the citrullinated peptide tetramers may lead to some nonspecific staining (false-positive findings) during our flow-based analysis. Thus, the flow-based tetramer staining method represents a screening tool for ACPAs.
Our bioinformatics analysis identified clonally expanded plasmablast lineages, including families observed at a single time point and lineages persisting across multiple time points, in blood samples obtained serially during the course of RA ( Figure 1B Figure 1B) .
Further bioinformatics analysis of the SHM levels in the RA blood showed that plasmablast sequences belonging to lineages shared across multiple time points possessed a higher SHM level within the HC V-region gene, as compared to SHM levels in the total sequenced population of plasmablasts. The number of mutations from the aligned germline sequence was normalized by the length of the V-region identified. We observed a statistically significant increase in the SHM level among the persistent lineage-derived HC sequences compared to that in the total population of plasmablasts at ≥12 months from time point 1 (T1) (n = 2) (Figure 2A ). Without sequence-length normalization, we observed a mean of 29.6 mutations in the HC V-region gene among the T1-derived sequences that belonged to persistent lineages, across each subject's average mutation level (see Supplementary Figure 2A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley. com/doi/10.1002/art.40587/abstract). We observed similar trends when we focused on the full-length sequences, with a mean of 30.6 mutations in the HC V-region gene among the 7 RA subjects with T1-derived, fulllength persistent lineage sequences (see Supplementary Figure 2B , http://onlinelibrary.wiley.com/doi/10.1002/art. 40587/abstract). Overall, we identified 46 persistent lineages (27%) demonstrating a high level of SHMs, with a mean of ≥40 nucleotide mutations in the HC V-region gene compared to germline, at ≥1 time point.
Focusing on the persistent lineages, we determined the mean fold change in the normalized number of SHMs across different time points, which allowed us to identify subsets of lineages that were either increasing (>1.1-fold change), decreasing (<0.9-fold change), or staying the same (results in Supplementary Figures  2C-E , http://onlinelibrary.wiley.com/doi/10.1002/art.40587/ abstract). Although most lineages were changing (i.e., increasing or decreasing) in SHM levels over time, an evaluation of each subset separately showed significantly more lineages maintaining similar levels of SHMs (P < 0.05) ( Figure 2B ). Across the individual RA subjects, we observed that different subjects exhibited varying percentages of lineages belonging to each change category. RA subjects 4 and 6 had the highest percentage of lineages with a decreasing number of SHMs, and RA subject 4 also had the second lowest percentage of lineages with an increasing number of SHMs. Compared to other subjects, RA subject 4 also exhibited a lower mutation level in the HC and LC V-region genes among persistent lineage-derived sequences. Interestingly, RA subject 4 showed low levels of disease, with no tender and swollen joints, at T1 and 4 months later (Table 1) .
We characterized isotype usage among the IgA-and IgG-expressing plasmablasts. We observed a significantly higher number of IgA-expressing plasmablasts captured at each time point for each subject (P < 0.01) (results shown in Supplementary Figure 2F , http://onlinelibrary.wiley. com/doi/10.1002/art.40587/abstract). Furthermore, our analysis of persistent lineages revealed that a significantly higher percentage of persistent lineages expressed antibodies of the IgA isotype compared to those expressing antibodies of the IgG isotype (P < 0.01) ( Figure 2C ). Although no correlation with mutation levels was found, we observed an inverse correlation between the number of tender and swollen joints and the normalized mean size of the clonal families (see Supplementary Figure 2G , http://onlinelibrary. wiley.com/doi/10.1002/art.40587/abstract). Taken together, our observations suggest that there is persistent antigen stimulation of the plasmablast response taking place in RA, and these persistent lineages predominantly express IgA. Among all of the persistent lineages identified, we observed a subset that continued to increase in mean levels of SHMs over months in anti-CCP+ patients with established RA.
ELLIOTT ET AL
Evidence of convergence across persistent lineages from different patients. To characterize amino acid CDR3 sequence motifs among the persistent lineages identified in the different RA subjects, we performed cluster analysis on the paired amino acid HC and LC CDR3 sequences from individual plasmablasts, using CD-HIT (28, 29) . This analysis revealed multiple clusters containing shared sequence motifs (70% identity) across subjects within the identified persistent lineages ( Figure 2D ). Sequences of 2 highly related clusters were grouped for motif generation (cluster 6 in Figure 2D ). Within the clusters, we identified sequences produced by plasmablasts that bound the citrullinated peptide tetramers (Figure 2D) . Thus, CD-HIT cluster analysis demonstrated that individuals with established RA generate persistent B cell lineages that exhibit shared amino acid motifs across individuals, some of which express ACPAs.
Identification of the antigen targets of recombinant antibodies derived from RA plasmablast lineages. We selected 71 plasmablast antibody sequences for recom- Figure 2 . A subset of the persistent lineages in anti-CCP+ RA patients display increased numbers of somatic hypermutations (SHMs) over time, and persistent lineages predominantly express the IgA isotype. A, Sequences from 8 anti-CCP+ RA patients were analyzed for differences in SHM levels among all consensus, IMGT-aligned sequences (HC and LC Total) compared to the persistent lineage-derived subset (HC and LC Shared). * = P < 0.05 by two-way analysis of variance (ANOVA) with Tukey's correction. B, Persistent lineages were evaluated for SHM levels and categorized according to the mean SHM level over time, determined as increasing (Inc.), maintaining similar (Sim.) levels, or decreasing (Dec.). * = P < 0.05 by one-way ANOVA with Tukey's correction. C, For IgA/IgG-expressing plasmablasts, the percentage of persistent lineages consistently expressing IgA was compared to that utilizing IgG or both IgG and IgA. ** = P < 0.01 by one-way ANOVA with Tukey's correction. In A-C, symbols represent individual patients; bars indicate the mean AE SEM. D, Persistent lineage-derived sequences were evaluated for similarities in the third complementarity-determining region, and clusters were visualized by igraph. Each dot represents the sequence from a single cell. Dots are colored by subject or by citrullinated peptide tetramer (Cit-tet) staining. Clusters with ≥1 member binding to citrullinated peptide tetramers are circled in red. Motifs of clusters comprising ≥1 subject were visualized using WebLogo version 3.5.0. See Figure 1 for other definitions. . Using the manufacturer's protocol, activity units and the cutoff level for plasma activity (blue dotted line) were determined. For recombinant antibodies, the cutoff level for activity (red dotted line) was set to 3 SD above the mean binding activity of negative control (Neg Ctrl) antibodies. Data are the mean AE SEM from duplicate determinations. C, Recombinant antibodies were evaluated for epitope specificity using an RA antigen microarray that includes~350 citrullinated (cit) and native proteins/peptides. Microarrays were probed with recombinant antibodies representing clonal families/lineages and singletons derived from plasmablasts binding to citrullinated peptide tetramers. The heatmap depicts median fluorescence intensities (MFIs) from quadruplicate print spots. Gray indicates an antibody-antigen combination for which data could not be obtained. Each antibody is labeled according to the subject (S) and time point (T) from which it is derived. The recombinant antibodies derived from a plasmablast that stained for the citrullinated peptide tetramers during sorting are marked in red. Peptide sequences similar to those used to generate the tetramers are marked with a blue asterisk. Apo A1 = apolipoprotein A-I; cf = filaggrin; FibA = fibrinogen A; Vim = vimentin (see Figure 1 for other definitions).
binant expression (a complete list is provided in Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40587/abstract) as representatives of 1) clonal families/persistent lineages unique to individuals, 2) lineages possessing HC and/or LC CDR3 amino acid sequence motifs shared across subjects, and 3) singleton antibodies derived from plasmablasts that bound citrullinated peptide tetramers. As negative controls, we used antibodies reactive to influenza (38) , desmoglein 3 (39), or derived from ongoing projects investigating non-RA diseases. All antibodies were expressed on the human IgG1 Fc domain.
Plasma from the 8 subjects with established RA ( Figure 3A ) and all subject-derived recombinant antibodies ( Figure 3B ; see also Supplementary Figure 3A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40587/abstract) were assayed using the CCP3.1 ELISA for citrullinated peptide binding. We used RA antigen planar arrays (Figure 3C ) and bead-based arrays (results shown in Supplementary Figure 3B , http://onlinelibrary.wiley.com/doi/10. 1002/art.40587/abstract) to further characterize binding specificities. These analyses identified clonal family/lineage recombinant antibodies that bound citrullinated epitopes in fibrinogen, histones, clusterin, or a-enolase. Importantly, certain later time point-derived persistent lineage members (e.g., rAb66 and rAb82) bound an expanded set of antigen targets compared to those targeted by antibodies derived from earlier time points ( Figure 3C) .
Evidence of affinity maturation driving epitope spreading. In-depth characterization of the persistent lineages from the different RA subjects revealed mutation patterns that suggested that affinity maturation drives epitope spreading. ELISA analysis of antibodies from a lineage obtained from RA subject 1 confirmed that the later time point-derived antibody rAb66 bound specific Figure 4 . Alternatively mutated plasmablast recombinant antibodies exhibit differential binding to citrullinated (Cit) antigens. A and B, Binding activity of recombinant antibodies, representing persistent lineages from rheumatoid arthritis (RA) subject 1 (A) and RA subject 8 (B), to fulllength proteins and specific epitopes was assessed by enzyme-linked immunosorbent assay (ELISA). The fold change in antibody binding activity relative to an activity cutoff level of 3 SD above the mean value for negative control antibodies (Neg. Ctrls) (dotted line) was calculated. Values are the mean AE SEM from duplicate determinations. C, Persistent lineage members were subjected to IgTree analysis to characterize the degree of relatedness between members and the distinct somatic hypermutations accumulated in each B cell-encoded antibody over the course of the affinity maturation process. Connectors between nodes of family trees indicate the number of mutations accumulated for each member compared to the germline (GL) heavy-chain (HC) and light-chain (LC) V-J-region gene sequences. Cyan-colored nodes represent lineage members binding to additional epitopes, as identified by ELISA. D, Nucleotide-based, full-length HC and LC antibody sequences were converted to amino acid sequences and aligned to germline sequences (Geneious). Segments corresponding to different complementarity-determining regions are indicated. The observed differences from germline of these evolving anti-citrullinated protein antibodies are highlighted and colored according to hydrophobicity, with red indicating more hydrophobic residues. epitopes of H2B and H2A, while the member from an earlier time point, rAb65, did not bind these epitopes ( Figure 4A ). We also observed substantial binding differences for rAb65 and rAb66 in their binding to full-length, in vitro-citrullinated H2A, H2B, and PAD, the latter of which can autocitrullinate (40) (see results in Supplementary Figure 4A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40587/abstract). Similarly, for a lineage derived from the blood of RA subject 8, the later time point-derived, more-mutated rAb82 bound full-length, citrullinated H2B and an H2B-derived epitope, whereas rAb81 did not bind these epitopes ( Figure 4B) .
IgTree-based analysis (33) revealed a bifurcation from a common parent, with 37 and 21 shared alterations for rAb65/rAb66 and rAb81/rAb82, respectively, followed by continued, divergent evolution ( Figure 4C ). Direct alignment with germline HC and LC V-region sequences demonstrated substantial differences between the lineage members in regions outside of the CDR3 (e.g., CDR1, CDR2, and framework regions) ( Figure 4D ).
Analyses by ELISA revealed that the persistent lineage-derived antibodies rAb71 and rAb72, which were identified in RA subject 3 and displayed differential reactivity by planar antigen array, exhibited similar binding reactivity to H2A, H2B, and an H2A-derived peptide (see Supplementary Figure 4B , http://onlinelibrary.wiley.com/ doi/10.1002/art.40587/abstract). In the ELISA analyses evaluating antibodies with similar CDR3 sequence motifs, the findings confirmed that 2 clusters (C38 and C39) contained at least 1 antibody that bound citrullinated antigens (see Supplementary Figures 4C and D, http://onlinelibrary.wiley.com/doi/10.1002/art. 40587/abstract). The later time point-derived member rAb133, from RA subject 6, exhibited differential binding activity compared to that derived from an earlier time point. In antigen microarray and ELISA analyses, we confirmed that certain later time point-derived persistent plasmablast lineage members encoded antibodies that differentially bound citrullinated antigens. Furthermore, antibodies present at later time points possessed increased levels of SHMs and/or divergent SHMs. Taken together, these findings suggest that affinity maturation over time drives epitope spreading of the ACPA response.
Increased stimulation of macrophage TNF production by affinity-matured recombinant antibodies. To examine the ability of representative, persistent plasmablast lineage-derived, recombinant antibodies to stimulate macrophage production of TNF, we generated platebound ICs of these antibodies with citrullinated H2A, H2B, or PAD. Human monocyte-derived macrophages produced significantly higher levels of TNF in response to ICs generated with recombinant ACPAs that were derived from persistent lineages from 2 different RA subjects as compared to that in response to citrullinated antigen alone (P < 0.001) (Figures 5A and B) . Importantly, the negative control antibody did not induce significantly higher macrophage production of TNF as compared to that with citrullinated antigen alone (Figures 5A and B) . In addition, citrullinated H2A and H2B significantly increased TNF production by macrophages compared to that in cultures with macrophages alone (P < 0.05) (Figures 5A and B) . However, plate-bound PAD, which included all in vitro citrullination reagents but lacked H2A or H2B, resulted in a level of TNF production similar to that produced by macrophages alone.
To investigate the role of FccRII and TLR-4, we preincubated cells with blocking reagents prior to incubation with immobilized ICs. Blockade of FccRII reduced the levels of TNF produced by macrophages compared to that with ICs alone, with statistically significant reductions observed in cultures with rAb81 and rAb82 complexed with citrullinated H2B (P < 0.05) ( Figure 5B ) and in cultures with rAb66 complexed with citrullinated H2A or PAD ( Figure 5A ). Furthermore, following preincubation of the cells with the TLR-4 inhibitor, we observed a significant reduction in the levels of TNF stimulated by citrullinated antigens alone or in complex with recombinant antibody (each P < 0.001) (Figures 5A and B) . As reported previously (16, 17) , blockade of TLR-4 exhibited a dominant effect in the inhibition of TNF production by citrullinated antigen-IC-stimulated macrophages. No differences in TNF levels were observed between cell cultures with the TLR-4 inhibitor alone and cell cultures with both the TLR-4 inhibitor and FccRII blocker.
We further evaluated the effect of accumulated SHMs on IC-based macrophage stimulation. Recombinant antibodies observed at later time points and possessing higher levels of SHMs (i.e., rAb66 and rAb82) generated ICs that stimulated macrophages to produce significantly more TNF compared to less-mutated antibodies derived from the same lineage at earlier time points (P < 0.05) (Figures 5A and B) . Thus, individual recombinant ACPAs form ICs that stimulate macrophage TNF production. These results reveal that affinity maturation results in the generation of ACPAs that form ICs that more potently stimulate macrophage TNF production through FccRII and TLR-4.
DISCUSSION
In this study, we characterized the evolving ACPA plasmablast response in individuals with established RA Figure 5 . Rheumatoid arthritis (RA) subject-derived recombinant antibody-citrullinated (Cit) antigen immune complexes (ICs) stimulate macrophages to produce tumor necrosis factor (TNF). Plate-bound ICs were formed by coating wells with a citrullinated antigen (H2B, H2A, or peptidylarginine deiminase [PAD]) followed by incubation with recombinant antibodies representing persistent lineages from RA subject 1 (A) or RA subject 8 (B). Monocyte-derived macrophages were added to each well, and after 24 hours, supernatants were harvested and TNF levels were measured using enzyme-linked immunosorbent assay. A portion of macrophages were preincubated with the Toll-like receptor 4 (TLR-4) inhibitor TAK-242 (TLR4B) and Fcc receptor type II (FccRII) inhibitor anti-CD32 clone IV.3 (FcB), prior to addition to the plate. Lipopolysaccharide (LPS) was used as a positive control, and cells alone with buffers served as negative controls (Neg Ctrl). The same controls are displayed in multiple panels for comparison. TNF levels were compared between antibodies observed at different time points (T1 and T2 or T1 and T3) within the same lineage, and TNF levels produced in the presence of inhibitors were compared to that with IC alone (* = P < 0.05; ** = P < 0.001, by twoway analysis of variance [ANOVA] with Tukey's correction; TNF levels in cells incubated with citrullinated proteins without IC versus TNF levels in cells alone, † = P < 0.05 by one-way ANOVA with Tukey's correction). Results are the mean AE SEM. Representative data are shown, and similar trends were observed in 2 independent experiments. by integrating information on antibody sequences with data on the specificity and functional activity of the encoded antibodies. We identified clonal families and persistent lineages expressing ACPAs with the use of citrullinated peptide tetramers, and representative recombinant antibodies were characterized for their binding specificity and functional properties. Our analysis revealed that select divergently mutated plasmablast antibodies derived from later time points exhibited differential binding specificity and increased potency to stimulate macrophages to produce TNF, as compared to earlier time point-derived lineage members that were less mutated.
Our findings suggest that persistent antigen stimulation of B cell lineages in individuals with RA results in continued affinity maturation and high SHM levels. Persistent lineages shared IMGT-based assignments of HC and LC V-J-region genes and 60% identity within the HC and LC CDR3 (according to the Levenshtein distance [26] ). Persistent lineage-derived sequences exhibited higher levels of HC V-region gene SHMs as compared to the total sequenced plasmablast population. Across the 8 subjects with RA, we observed a mean of 29.6 mutations within the HC V-region gene of persistent lineages at T1, and observed that 27% of the persistent lineages averaged ≥40 mutations in the HC V-region gene in at least 1 time point.
These mutation levels are substantially higher compared to those observed in HC V-region genes of H1N1 virus-induced B cells (mean~19 mutations per patient) from 5 subjects (41) or IgG-expressing memory B cells from 3 healthy donors (mean AE SD 18 AE 8.1 mutations) (42) . This high SHM level is likely generated through germinal center (GC)-mediated affinity maturation and lineage expansion, during which B cells undergo iterations of division and mutation in the GC dark zone and selection in the light zone, with up to 6 divisions observed in the dark zone (43) . At a mutation rate of 10 À3 per basepair per cell division, it is estimated that there will be ≥1 mutation across HC and LC V-region genes per every 2 divisions (44). Thus, we estimate that these highly mutated plasmablast lineages present in patients with established RA resulted from >80 cell divisions and repeated rounds of division/selection in the GCs. At later time points, multiple persistent lineages exhibited increased and differential mutations among lineage members, while other lineages exhibited fewer mutations at later time points. Since we only sampled the repertoire at set time points, these observations may arise through 1) recruitment of a common progenitor that undergoes successive rounds of division, mutation, and selection in the GC, or 2) stimulation of distinct branches of the lineage tree at different time points.
A significantly higher percentage of the persistent plasmablast lineages expressed IgA compared to IgG. Since IgA represents the dominant isotype in mucosally driven immune responses, this suggests that a persistent mucosal antigen stimulates the ongoing IgA plasmablast response in established RA. This is consistent with the findings from previous studies that demonstrated an elevated percentage of IgA plasmablasts in anti-CCP+ individuals at risk for RA (20) , an association of periodontal disease with RA (45) , and the presence of ACPAs in the sputum of individuals with early RA (10) . In summary, our findings demonstrate a continued, ongoing IgA plasmablast response in established RA, suggesting that a persistent mucosal antigen stimulus plays a key role in mediating the persistence of RA.
Our results support a mechanism by which evolving B cell lineages produce ACPAs that contribute to the pathogenesis of RA by stimulating macrophage TNF production. Previous studies from our laboratory demonstrated that citrullinated fibrinogen or H2B ICs, generated using pooled IgG from RA plasma, stimulated macrophages to produce TNF (16, 17) . Building upon these previous observations, we expressed the recombinant antibodies on the IgG1 backbone as a research tool and demonstrated that individual, RA subject-derived ACPAs formed ICs capable of stimulating macrophage TNF production. Furthermore, persistent lineage members observed at later time points, which possessed increased levels of SHMs, encoded antibodies that 1) exhibited differential binding to citrullinated antigens, and 2) more potently stimulated macrophages to produce TNF. We note that the antibodies derived from later time points did not fully share all of the SHMs that were observed at the earlier time point; however, our IgTree analysis showed that plasmablasts derived at different time points share a common parent cell. Thus, differential, continued affinity maturation from this common parent cell results in the generation of antibodies that exhibit epitope spreading and more potently promote inflammation in RA.
Data from this study provide evidence of a common process by which individuals with RA generate persistent B cell lineages with shared CDR3 sequence motifs. Previous studies provided evidence of convergent evolution of the antibody response, such as the generation of antibodies in response to Dengue virus infection (46) or antibodies against the CD4 binding site of HIV-1 (47) . In patients with established RA, we demonstrated that certain persistent B cell lineages shared CDR3 amino acid sequence motifs across individuals. In 2 of these shared clusters, we confirmed by ELISA that a representative member bound citrullinated antigens, suggesting that these motifs contain key CDR3 residues that mediate citrullinated epitope binding.
There are several limitations to this study. First, we focused on characterizing the ongoing immune response through sequencing of the plasmablast repertoire. We did not sequence memory B cells, which might contain common B cell progenitors. Second, we performed single-cell sequencing with limited depth. Future studies could utilize a droplet-based method to sequence a larger number of B cells. Third, recombinant antibody binding specificity was analyzed using an antigen microarray containing~350 distinct proteins/peptides, and it is likely that certain antigen targets are not included on this array. Fourth, to isolate ICs for macrophage stimulation, we formed plate-bound ICs; however, this approach may lead to structural constraints, potentially reducing the capacity of these ICs to stimulate macrophage TNF production as compared to that in the presence of ICs formed in vivo. Finally, we used 14 different citrullinated peptide tetramers to identify ACPA-producing plasmablasts; however, future studies could more thoroughly characterize ACPA-expressing B cells by including additional citrullinated peptides and/ or proteins.
In summary, sequencing blood plasmablasts from patients with established RA over serial time points revealed that ACPA-encoding B cell lineages persist and evolve, exhibiting extensive, progressive, and differential SHMs. Intriguingly, these persistent lineages predominantly expressed IgA, suggesting a continued mucosal drive in established RA, an observation that may provide important insight into the mechanisms underlying the persistence of RA. Continued affinity maturation resulted in epitope spreading such that B cell lineage members observed at later time points expressed ACPAs with expanded citrullinated antigen reactivities. Importantly, differentially evolved ACPAs observed at later time points formed ICs that more potently stimulated macrophage TNF production, highlighting the potential for an increased pathogenic role of these affinity-matured ACPAs. The level of TNF produced by IC stimulation of macrophages was reduced by TLR-4 blockade, thus demonstrating the potential of TLR-4 as a therapeutic target in RA, as has been suggested previously (16, 17, 48, 49) . Taken together, our findings demonstrate that affinity maturation plays a critical role in epitope spreading and generation of ACPAs that more potently drive macrophage TNF production in RA.
